These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

646 related items for PubMed ID: 25922407

  • 1. Differences of the Fecal Microflora With Clostridium difficile Therapies.
    Louie TJ, Byrne B, Emery J, Ward L, Krulicki W, Nguyen D, Wu K, Cannon K.
    Clin Infect Dis; 2015 May 15; 60 Suppl 2():S91-7. PubMed ID: 25922407
    [Abstract] [Full Text] [Related]

  • 2. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM, Polymer Alternative for CDI Treatment (PACT) investigators.
    Clin Infect Dis; 2014 Aug 01; 59(3):345-54. PubMed ID: 24799326
    [Abstract] [Full Text] [Related]

  • 3. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W.
    Clin Infect Dis; 2012 Aug 01; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [Abstract] [Full Text] [Related]

  • 4. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
    Cannon K, Byrne B, Happe J, Wu K, Ward L, Chesnel L, Louie T.
    J Antimicrob Chemother; 2017 Dec 01; 72(12):3453-3461. PubMed ID: 28927227
    [Abstract] [Full Text] [Related]

  • 5. Diagnosis and management of Clostridium difficile infection.
    Dupont HL.
    Clin Gastroenterol Hepatol; 2013 Oct 01; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [Abstract] [Full Text] [Related]

  • 6. Real-time polymerase chain reaction testing for Clostridium difficile reduces isolation time and improves patient management in a small community hospital.
    Catanzaro M, Cirone J.
    Am J Infect Control; 2012 Sep 01; 40(7):663-6. PubMed ID: 22153847
    [Abstract] [Full Text] [Related]

  • 7. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.
    Zhang L, Dong D, Jiang C, Li Z, Wang X, Peng Y.
    Anaerobe; 2015 Aug 01; 34():1-7. PubMed ID: 25817005
    [Abstract] [Full Text] [Related]

  • 8. Molecular epidemiologic study of Clostridium difficile infections in university hospitals: Results of a nationwide study in Japan.
    Tokimatsu I, Shigemura K, Osawa K, Kinugawa S, Kitagawa K, Nakanishi N, Yoshida H, Arakawa S, Fujisawa M, Research Group of Japan Infection Prevention and Control Conference for National and Public University Hospitals.
    J Infect Chemother; 2018 Aug 01; 24(8):641-647. PubMed ID: 29685855
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
    Jardin CG, Palmer HR, Shah DN, Le F, Beyda ND, Jiang Z, Garey KW.
    J Hosp Infect; 2013 Sep 01; 85(1):28-32. PubMed ID: 23834988
    [Abstract] [Full Text] [Related]

  • 12. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection.
    Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ.
    Infect Control Hosp Epidemiol; 2010 Jan 01; 31(1):21-7. PubMed ID: 19929371
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
    Crowther GS, Baines SD, Todhunter SL, Freeman J, Chilton CH, Wilcox MH.
    J Antimicrob Chemother; 2013 Jan 01; 68(1):168-76. PubMed ID: 22966180
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.